Genetech, the pharmaceutical company that manufactures Raptiva, has just initiated a voluntary recall for the dangerous psoriasis drug. The recall will be completed by June 8, 2009.
Raptiva has been recalled due to a risk of developing progressive multifocal leukoencephalopathy (PML), a rare neurologic disease that attacks your central nervous system, causing a breakdown of neurologic functioning. PML is fatal.
PML most commonly develops in patients who already have a weakened immune system. Symptoms of the disease include:
- Vision loss
- Impaired speech
- Cognitive deterioration
Risks Associated with Raptiva
On October 16, 2008, the Food and Drug Administration (FDA) updated the warning label for Raptiva to inform patients of the risk of developing PML from taking the psoriasis drug. After receiving reports of four patients who had developed PML from taking Raptiva, the FDA went a step further and issued a Public Health Advisory for the drug on February 19, 2009. Three of the four patients have already died.
Raptiva has also been associated with an increased risk of developing several other life-threatening conditions, including:
- Viral meningitis
- Invasive fungal disease
- Bacterial sepsis
- Brain infections
If you are currently taking Raptiva for the treatment of psoriasis, you should consult your physician immediately to discuss alternative treatments. If you have developed PML or any other serious condition from using the drug, you should report it to the FDA’s Medwatch Program.
If you have developed PML from taking Raptiva, you may be entitled to receive compensation for your injuries. It is important to consult an experienced pharmaceutical liability attorney at once to find out if you have a valid claim.
Please contact an experienced pharmaceutical injury lawyer in your area to evaluate your case.